Table 3.
Incidence of severe neutropenia in cycles 1–4 (per-protocol population)*
|
Cycle 1 |
Cycle 2 |
Cycle 3 |
Cycle 4 |
Across all cycles |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Pegfilgrastim 6 mg | Lipegfilgrastim 6 mg | Pegfilgrastim 6 mg | Lipegfilgrastim 6 mg | Pegfilgrastim 6 mg | Lipegfilgrastim 6 mg | Pegfilgrastim 6 mg | Lipegfilgrastim 6 mg | Pegfilgrastim 6 mg | Lipegfilgrastim 6 mg | |
| n/N |
48/94 |
41/94 |
20/93 |
8/94 |
11/91 |
8/93 |
11/91 |
11/90 |
55/94 |
47/94 |
| (%) |
(51.1) |
(43.6) |
(21.5) |
(8.5) |
(12.1) |
(8.6) |
(12.1) |
(12.2) |
(58.5) |
(50.0) |
| OR (95% CI) |
0.745 (0.405%, 1.369%) |
0.291 (0.110%, 0.769%) |
0.676 (0.249%, 1.835%) |
0.997 (0.391%, 2.545%) |
0.708 (0.383%, 1.309%) |
|||||
| p value† | 0.3409 | 0.0130 | 0.4404 | 0.9958 | 0.2695 | |||||
*Multiple mentions per patient are possible.
†Pegfilgrastim 6 mg vs. lipegfilgrastim 6 mg (p values are based on a null hypothesis of OR = 1).
CI confidence interval, OR odds ratio.